ARS Pharmaceuticals, Inc. has grown revenue 711% a year over three years and 98% a year over five. Revenue growth, 3-year annual rate: +711% (Biotechnology median +17%). Revenue growth, 5-year rate: +98%, growth has picked up over the last three years. Years of annual history on file: 6, FY2020 to FY2025, as filed.

SPRYARS Pharmaceuticals, Inc.

Healthcare

$4.57-56% 1Y

$4.57

$4.0752 weeks$13.06

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though operating margin widening (+251.8 points).

1 good, 1 neutral, 1 without data

Revenue trend+4% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Margin direction+251.8 points operating

Trailing-twelve-month operating margin, -189.8% now against -441.6% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is SPRY growing?

ARS Pharmaceuticals, Inc. has grown revenue 711% a year over three years and 98% a year over five.

+711%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +98%
Revenue growth, 5-year rate · +711% over three · growth has picked up over the last three years
Years of annual history on file: 6
Years of annual history on file · FY2020 to FY2025, as filed

Details›